Literature DB >> 18399985

Haplotype analysis confirms the association between the HCRTR2 gene and cluster headache.

Innocenzo Rainero1, Salvatore Gallone, Elisa Rubino, Paola Ponzo, Walter Valfre, Eleonora Binello, Pierpaola Fenoglio, Salvatore Gentile, Mihaela Anoaica, Mauro Gasparini, Lorenzo Pinessi.   

Abstract

BACKGROUND: Several studies suggested that genetic factors play a role in cluster headache (CH) susceptibility. We found a significant association between the 1246 G>A polymorphism of the hypocretin receptor-2 (HCRTR2) gene and the disease. This association was confirmed in a large study from Germany but was not replicated in a dataset of CH patients from Northern Europe.
OBJECTIVE: The purpose of this study was to further evaluate the association between CH and the HCRTR2 gene using new polymorphisms, estimating the frequency of different gene haplotypes, searching for gene mutations, and evaluating the effects of the examined polymorphisms on hypocretin binding sites.
METHODS: We genotyped 109 CH patients and 211 healthy controls for 5 new polymorphisms of the HCRTR2 gene and we inferred different gene haplotypes. Complete HCRTR2 sequencing was undertaken for 11 independent CH patients, 5 of whom had a positive family history. The effects of the 1246 G>A polymorphism on the hypocretin binding sites were evaluated using different computer-assisted analyses.
RESULTS: Three new polymorphisms of the HCRTR2 gene resulted significantly associated with CH. The GTAAGG haplotype resulted more frequent in cases than in controls (OR: 3.68; 95% CI: 1.85-7.67). No point mutation of the HCRTR2 gene was found. Binding analyses showed that the 1246 G>A polymorphism (substitution of valine at position 308 by isoleucine) has no effect on the hypocretin binding sites but could influence the dimerization process of the receptor.
CONCLUSION: Our data confirm previous studies suggesting that the HCRTR2 gene or a linked locus significantly modulates the risk for CH. In addition, we suggest that the V308I substitution of the HCRTR2 may interfere with the dimerization process of the receptor, thereby influencing its functional activity.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18399985     DOI: 10.1111/j.1526-4610.2008.01080.x

Source DB:  PubMed          Journal:  Headache        ISSN: 0017-8748            Impact factor:   5.887


  15 in total

Review 1.  Genetics of cluster headache.

Authors:  Markus Schürks
Journal:  Curr Pain Headache Rep       Date:  2010-04

2.  Family History of Cluster Headache: A Systematic Review.

Authors:  Maggie W Waung; Amy Taylor; Krista J Qualmann; Mark J Burish
Journal:  JAMA Neurol       Date:  2020-07-01       Impact factor: 18.302

Review 3.  Cluster headache, hypothalamus, and orexin.

Authors:  Philip R Holland; Peter J Goadsby
Journal:  Curr Pain Headache Rep       Date:  2009-04

4.  Radiosynthesis and evaluation of [11C]EMPA as a potential PET tracer for orexin 2 receptors.

Authors:  Changning Wang; Christian K Moseley; Stephen M Carlin; Colin M Wilson; Ramesh Neelamegam; Jacob M Hooker
Journal:  Bioorg Med Chem Lett       Date:  2013-04-02       Impact factor: 2.823

5.  Biochemical and behavioural characterization of EMPA, a novel high-affinity, selective antagonist for the OX(2) receptor.

Authors:  P Malherbe; E Borroni; L Gobbi; H Knust; M Nettekoven; E Pinard; O Roche; M Rogers-Evans; J G Wettstein; J-L Moreau
Journal:  Br J Pharmacol       Date:  2009-04       Impact factor: 8.739

Review 6.  Neurobiology and sleep disorders in cluster headache.

Authors:  Mads Christian Johannes Barloese
Journal:  J Headache Pain       Date:  2015-08-20       Impact factor: 7.277

Review 7.  Cluster headache.

Authors:  Elizabeth Leroux; Anne Ducros
Journal:  Orphanet J Rare Dis       Date:  2008-07-23       Impact factor: 4.123

8.  Associations between the orexin (hypocretin) receptor 2 gene polymorphism Val308Ile and nicotine dependence in genome-wide and subsequent association studies.

Authors:  Daisuke Nishizawa; Shinya Kasai; Junko Hasegawa; Naomi Sato; Hidetaka Yamada; Fumihiko Tanioka; Makoto Nagashima; Ryoji Katoh; Yasuo Satoh; Megumi Tagami; Hiroshi Ujike; Norio Ozaki; Toshiya Inada; Nakao Iwata; Ichiro Sora; Masaomi Iyo; Mitsuhiko Yamada; Naoki Kondo; Moo-Jun Won; Nobuya Naruse; Kumi Uehara-Aoyama; Masanari Itokawa; Kazutaka Ohi; Ryota Hashimoto; Kumpei Tanisawa; Tomio Arai; Seijiro Mori; Motoji Sawabe; Makiko Naka-Mieno; Yoshiji Yamada; Miki Yamada; Noriko Sato; Masaaki Muramatsu; Masashi Tanaka; Yoko Irukayama-Tomobe; Yuki C Saito; Takeshi Sakurai; Masakazu Hayashida; Haruhiko Sugimura; Kazutaka Ikeda
Journal:  Mol Brain       Date:  2015-08-20       Impact factor: 4.041

9.  Distinct effects of IPSU and suvorexant on mouse sleep architecture.

Authors:  Daniel Hoyer; Thomas Dürst; Markus Fendt; Laura H Jacobson; Claudia Betschart; Samuel Hintermann; Dirk Behnke; Simona Cotesta; Grit Laue; Silvio Ofner; Eric Legangneux; Christine E Gee
Journal:  Front Neurosci       Date:  2013-12-10       Impact factor: 4.677

Review 10.  OX1 and OX2 orexin/hypocretin receptor pharmacogenetics.

Authors:  Miles D Thompson; Henri Xhaard; Takeshi Sakurai; Innocenzo Rainero; Jyrki P Kukkonen
Journal:  Front Neurosci       Date:  2014-05-06       Impact factor: 4.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.